Two for One
LHON gene therapy injected into one eye causes significant vision improvement in both
Leber hereditary optic neuropathy (LHON) patients taking part in a phase 3 clinical trial received injections of a gene therapy vector into the vitreous cavity of one eye. As a result, 78 percent unexpectedly noted significant improvement of visual function in both eyes. Even more surprisingly, both eyes followed the same trajectory over two years of follow-up. The effect is possibly due to the viral vector DNA transferring from the injected eye into the other; the DNA was detected in the anterior segment, retina, and optic nerve of the untreated eye three months after injection. The therapy saves retinal ganglion cells from a mutation that causes LHON by replacing the defective gene. Once the mechanism of the bilateral improvement is better understood, it could potentially be used with other sight-saving gene therapies.
- P Yu-Wai-Man et al., Sci Transl Med, 12 (2020). PMID: 33298565.
Having edited several technical publications over the last decade, I crossed paths with quite a few of Texere's current team members, and I only ever heard them sing the company's praises. When an opportunity arose to join Texere, I jumped at the chance! With a background in literature, I love the company's ethos of producing genuinely engaging content, and the fact that it is so well received by our readers makes it even more rewarding.